tm
Seeing Is Believing
tm
Seeing Is Believing
Currently, out of the existing stock ratings of Mike Matson - 526 which are a Buy (93.76%), 31 which are a Hold (5.53%), 4 which are a Sell (0.71%)
Analyst Mike Matson works at NEEDHAM and is covering the Healthcare sector with 972 price targets and ratings displayed on 38 stocks.
Mike Matson's average stock forecast success ratio is 56.61% with an average time for price targets to be met of 259 days.
Most recent stock forecast was given on ATRC, AtriCure at 29-Nov-2023.
Analyst best performing recommendations are on OCX (ONCOCYTE).
The best stock recommendation documented was for OCX (ONCOCYTE) at 11/9/2023. The price target of $3.6 was fulfilled within 6 days with a profit of $0.9 (33.33%) receiving and performance score of 55.56.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
49
$12.52 (34.32%)
49
7 days ago
10/22 (45.45%)
$11.2 (26.35%)
244
Buy
50
$13.52 (37.06%)
96
1 months 4 days ago
2/5 (40%)
$15.03 (27.97%)
45
Buy
56
$19.52 (53.51%)
75
2 months 7 days ago
4/9 (44.44%)
$15.7 (32.33%)
415
Buy
50
$13.52 (37.06%)
48
7 months 3 days ago
7/7 (100%)
$5.48 (11.31%)
71
Buy
74
$37.52 (102.85%)
81
9 months 14 days ago
2/7 (28.57%)
$27.83 (51.41%)
14
Which stock is Mike Matson is most bullish on?
Which stock is Mike Matson is most reserved on?
What Year was the first public recommendation made by Mike Matson?
